CCR8 清除抗体通过靶向肿瘤内 CCR8+ 调节性 T 细胞恢复头颈癌对放疗联合 anti-PD-1 治疗的应答
CCR8-depleting antibodies restore response to radiotherapy plus anti-PD1 therapy in head and neck cancer by targeting intratumoral CCR8+ regulatory T cells
研究发现,CCR8 清除抗体可逆转头颈鳞癌对放疗联合 anti-PD-1 治疗的耐药。研究在人和小鼠头颈鳞癌中鉴定出与放疗和免疫治疗应答不全相关的 CCR8+ Treg 亚群。临床前模型显示,放疗驱动 CCR8+ Treg 浸润原发肿瘤,anti-PD-1 会激活该类细胞,二者促进肿瘤生长和复发,而 CCR8 清除抗体可逆转这一过程。
临床前模型将放疗和抗 PD-1 治疗引起的 CCR8+ Treg 积聚与耐药联系起来,为头颈癌联合免疫治疗提供靶点依据。
已发表论文 · journal · 10.1038/s41467-026-79341-8
本站摘要基于收录版本 v1(2026-11-16),原始摘要与 AI 导读固定保留。
IF(5) 18.9 · 2025 · 期刊参考指标
摘要翻译暂不可用,暂时显示原文。
CCR8-depleting antibodies restore response to radiotherapy plus anti-PD1 therapy in head and neck cancer by targeting intratumoral CCR8+ regulatory T cells
Despite advances in immunotherapy (IO) and radiation therapy (RT), anti-PD-1 (aPD-1) therapy has provided only modest benefit in head and neck squamous cell carcinoma (HNSCC) for reasons that remain poorly understood. CCR8 is a chemokine receptor selectively enriched on tumor infiltrating regulatory T cells (Tregs), making it an attractive candidate for therapeutic targeting. Given our knowledge that immunosuppressive T-regulatory cells are associated with resistance to RT and IO, but have no effective targeting strategy in HNSCC, we investigate the depletion of tumor specific Treg subsets on tumor growth in female mice. In human and murine HNSCC, we characterize a subset of CCR8+ Tregs that are an immunosuppressive cell population associated with incomplete response to RT and IO. In preclinical models of HNSCC, we find that RT drives CCR8+ Treg infiltration into the primary tumor to promote tumor growth and recurrence, which can be reversed with administration of CCR8-depleting antibodies (aCCR8). Finally, we show that resistance to RT+aPD1 combination therapy is mediated by aPD1 activation of CCR8+ Tregs to facilitate tumor growth, which can be reversed with aCCR8. These findings reveal the immunosuppressive profile of CCR8+ Tregs in HNSCC and pave the way for novel combination strategies of IO in HNSCC. Previous evidence has implicated regulatory T cells (Tregs) in treatment resistance in head and neck cancer. Here the authors report that radiotherapy and anti-PD1 therapy drive the accumulation and activation of intratumoral CCR8+ Tregs, promoting tumor growth and recurrence, which can be reversed with administration of CCR8 depleting antibodies.
来源:Nature Communications · doi.org